{"id":"ranibizumab-control","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Conjunctival hemorrhage"},{"rate":"5-10","effect":"Eye pain"},{"rate":"5-10","effect":"Floaters"},{"rate":"5-15","effect":"Intraocular pressure elevation"},{"rate":"0.05-0.1","effect":"Endophthalmitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ranibizumab blocks VEGF-A, a key driver of pathological neovascularization and increased vascular permeability in retinal diseases. By neutralizing VEGF-A, it prevents the formation of abnormal blood vessels and reduces fluid leakage, thereby slowing or halting vision loss in conditions like age-related macular degeneration and diabetic retinopathy.","oneSentence":"Ranibizumab is a monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and vascular permeability in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:17.229Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Age-related macular degeneration (wet/neovascular)"},{"name":"Diabetic macular edema"},{"name":"Retinal vein occlusion"},{"name":"Diabetic retinopathy"}]},"trialDetails":[{"nctId":"NCT07007065","phase":"PHASE3","title":"Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-11-05","conditions":"Neovascular Age-related Macular Degeneration","enrollment":561},{"nctId":"NCT06176352","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2024-03-06","conditions":"Choroidal Neovascularization Secondary to Pathologic Myopia","enrollment":280},{"nctId":"NCT04514653","phase":"PHASE2","title":"RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2020-08-25","conditions":"Neovascular Age-Related Macular Degeneration (nAMD)","enrollment":146},{"nctId":"NCT04704921","phase":"PHASE2, PHASE3","title":"Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD","status":"RECRUITING","sponsor":"AbbVie","startDate":"2020-12-29","conditions":"AMD, nAMD, Wet Age-related Macular Degeneration","enrollment":630},{"nctId":"NCT04690556","phase":"PHASE3","title":"Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD","status":"COMPLETED","sponsor":"Lupin Ltd.","startDate":"2020-09-14","conditions":"Neovascular Age-related Macular Degeneration","enrollment":600},{"nctId":"NCT07269769","phase":"PHASE3","title":"A Clinical Trial Evaluating the Efficacy and Safety of Sanhuang Jingshiming Pills in the Treatment of nAMD","status":"NOT_YET_RECRUITING","sponsor":"Tasly Pharmaceutical Group Co., Ltd","startDate":"2026-01-01","conditions":"AMD","enrollment":450},{"nctId":"NCT05439629","phase":"PHASE3","title":"Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2022-07-07","conditions":"Neovascular (Wet) Age-related Macular Degeneration","enrollment":488},{"nctId":"NCT03161652","phase":"PHASE2","title":"Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema","status":"RECRUITING","sponsor":"Carmen Clapp","startDate":"2017-05-24","conditions":"Diabetic Macular Edema, Diabetic Retinopathy","enrollment":120},{"nctId":"NCT05151731","phase":"PHASE2","title":"A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-12-31","conditions":"Diabetic Macular Edema","enrollment":394},{"nctId":"NCT05151744","phase":"PHASE2","title":"A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-12-17","conditions":"Diabetic Macular Edema","enrollment":187},{"nctId":"NCT05407636","phase":"PHASE3","title":"Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD","status":"RECRUITING","sponsor":"AbbVie","startDate":"2022-01-13","conditions":"AMD, nAMD, Wet Age-related Macular Degeneration","enrollment":660},{"nctId":"NCT02243878","phase":"PHASE3","title":"Stereotactic Radiotherapy for Wet AMD (STAR)","status":"COMPLETED","sponsor":"King's College Hospital NHS Trust","startDate":"2014-12","conditions":"Neovascular (Wet) Age-related Macular Degeneration (AMD)","enrollment":411},{"nctId":"NCT06305416","phase":"PHASE3","title":"A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema","status":"RECRUITING","sponsor":"Incepta Pharmaceuticals Ltd","startDate":"2024-03-30","conditions":"Diabetic Macular Edema, Diabetic Retinopathy, Macular Edema","enrollment":70},{"nctId":"NCT05003245","phase":"PHASE3","title":"Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2021-11-01","conditions":"Age Related Macular Degeneration","enrollment":407},{"nctId":"NCT03844074","phase":"PHASE3","title":"A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Outlook Therapeutics, Inc.","startDate":"2018-10-01","conditions":"Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration","enrollment":61},{"nctId":"NCT03834753","phase":"PHASE3","title":"A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Outlook Therapeutics, Inc.","startDate":"2019-06-25","conditions":"Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration","enrollment":228},{"nctId":"NCT05571267","phase":"PHASE2","title":"Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD","status":"TERMINATED","sponsor":"IVERIC bio, Inc.","startDate":"2016-10-20","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":1},{"nctId":"NCT04740671","phase":"PHASE3","title":"A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2021-07-01","conditions":"Age Related Macular Degeneration","enrollment":410},{"nctId":"NCT02302079","phase":"PHASE2","title":"A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2015-01-12","conditions":"Diabetes Mellitus, Diabetic Macular Edema","enrollment":96},{"nctId":"NCT01940900","phase":"PHASE3","title":"A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy","status":"TERMINATED","sponsor":"Ophthotech Corporation","startDate":"2013-08","conditions":"Age-Related Macular Degeneration","enrollment":627},{"nctId":"NCT01944839","phase":"PHASE3","title":"A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy","status":"TERMINATED","sponsor":"Ophthotech Corporation","startDate":"2013-08","conditions":"Age-Related Macular Degeneration","enrollment":619},{"nctId":"NCT03927690","phase":"PHASE2","title":"Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-05-24","conditions":"Diabetic Macular Edema","enrollment":91},{"nctId":"NCT00930189","phase":"PHASE2, PHASE3","title":"Comparative Study With Photodynamic Therapy And Triamcinolone Versus Photodynamic Therapy, Triamcinolone And Ranibizumab In Patients With Subfoveal Choroidal Neovascularization","status":"WITHDRAWN","sponsor":"Asociación para Evitar la Ceguera en México","startDate":"2006-04","conditions":"Subfoveal Choroidal Neovascularization","enrollment":""},{"nctId":"NCT04884399","phase":"PHASE1","title":"Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMD","status":"COMPLETED","sponsor":"Shanghai Biomabs Pharmaceutical Co., Ltd.","startDate":"2021-06-03","conditions":"Wet Age-related Macular Degeneration","enrollment":24},{"nctId":"NCT01089517","phase":"PHASE2","title":"A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Ophthotech Corporation","startDate":"2010-03","conditions":"Age-Related Macular Degeneration","enrollment":449},{"nctId":"NCT03784443","phase":"PHASE2, PHASE3","title":"Combined Ranibizumab and Iluvien for Diabetic Macular Oedema","status":"WITHDRAWN","sponsor":"Imperial College London","startDate":"2019-09-01","conditions":"Diabetic Macular Edema, Diabetes","enrollment":""},{"nctId":"NCT02623426","phase":"PHASE3","title":"Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial","status":"COMPLETED","sponsor":"JHSPH Center for Clinical Trials","startDate":"2017-03-09","conditions":"Uveitis, Macular Edema","enrollment":194},{"nctId":"NCT05480293","phase":"PHASE3","title":"This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2023-02-14","conditions":"Wet Age-related Macular Degeneration","enrollment":446},{"nctId":"NCT03690947","phase":"PHASE4","title":"Combination of Intravitreal Ranibizumab With or Without Micropulse Laser for the Treatment of DME","status":"COMPLETED","sponsor":"Beijing Hospital","startDate":"2018-10-01","conditions":"Diabetic Macular Edema","enrollment":72},{"nctId":"NCT03054766","phase":"NA","title":"Combination of Intravitreal Ranibizumab With or Without Macular Laser Photocoagulation for ME Secondary to BRVO","status":"COMPLETED","sponsor":"Beijing Hospital","startDate":"2017-02-14","conditions":"Branch Retinal Vein Occlusion, Ranibizumab, Laser Photocoagulation","enrollment":80},{"nctId":"NCT04486963","phase":"PHASE2","title":"A Phase Ⅱ Clinical Study of Sanhuangjingshimingwan in Wet( Neovascular)Age-related Macular Degeneration(wAMD) Subjects","status":"COMPLETED","sponsor":"Tasly Pharmaceutical Group Co., Ltd","startDate":"2020-07-24","conditions":"Age-related Macular Degeneration","enrollment":78},{"nctId":"NCT02140151","phase":"PHASE1, PHASE2","title":"Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Southern California Desert Retina Consultants, MC","startDate":"2014-09-17","conditions":"Age-related Macular Degeneration","enrollment":108},{"nctId":"NCT03725501","phase":"PHASE2","title":"Evaluation of the Safety and Efficacy of ALS-L1023 Administered in Combination With Ranibizumab in Patients With Wet-AMD","status":"COMPLETED","sponsor":"AngioLab, Inc.","startDate":"2018-12-07","conditions":"Age-Related Macular Degeneration","enrollment":126},{"nctId":"NCT05297292","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD","status":"UNKNOWN","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2021-05-07","conditions":"Wet Age-related Macular Degeneration","enrollment":433},{"nctId":"NCT02348359","phase":"PHASE2","title":"X-82 to Treat Age-related Macular Degeneration","status":"TERMINATED","sponsor":"Tyrogenex","startDate":"2015-03-16","conditions":"Age-Related Macular Degeneration (AMD), Macular Degeneration, Exudative Age-related Macular Degeneration","enrollment":157},{"nctId":"NCT03211234","phase":"PHASE2","title":"Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2017-07-05","conditions":"Age-Related Macular Degeneration","enrollment":76},{"nctId":"NCT04878835","phase":"PHASE1","title":"Effects of Ranibizumab in Primary Pterygium Surgery","status":"COMPLETED","sponsor":"Universiti Sains Malaysia","startDate":"2018-05-01","conditions":"Patients With Primary Nasal Pterygium","enrollment":52},{"nctId":"NCT02510794","phase":"PHASE2","title":"Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2015-09-28","conditions":"Macular Degeneration","enrollment":225},{"nctId":"NCT04857177","phase":"PHASE3","title":"A Study To Evaluate CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular Degeneration","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2018-10-19","conditions":"Neovascular(Wet) Age Related Macular Degeneration","enrollment":312},{"nctId":"NCT03203447","phase":"PHASE3","title":"Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO","status":"TERMINATED","sponsor":"Clearside Biomedical, Inc.","startDate":"2018-03-05","conditions":"Macular Edema, Retinal Vein Occlusion","enrollment":325},{"nctId":"NCT02222610","phase":"PHASE2","title":"Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.","status":"COMPLETED","sponsor":"Greater Houston Retina Research","startDate":"2014-09-23","conditions":"Radiation Retinopathy","enrollment":40},{"nctId":"NCT04714242","phase":"","title":"OCTA and Polypoidal Choroidal Vasculopathy","status":"COMPLETED","sponsor":"Federico II University","startDate":"2019-01-15","conditions":"Polypoidal Choroidal Vasculopathy","enrollment":60},{"nctId":"NCT01006538","phase":"PHASE4","title":"Macular EpiRetinal Brachytherapy Versus Lucentis® Only Treatment (MERLOT)","status":"COMPLETED","sponsor":"King's College Hospital NHS Trust","startDate":"2009-11","conditions":"Macular Degeneration","enrollment":363},{"nctId":"NCT01934556","phase":"PHASE1, PHASE2","title":"A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema","status":"COMPLETED","sponsor":"Palmetto Retina Center, LLC","startDate":"2013-11","conditions":"Diabetic Macular Edema","enrollment":150},{"nctId":"NCT02484690","phase":"PHASE2","title":"A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-08-11","conditions":"Choroidal Neovascularization","enrollment":273},{"nctId":"NCT03423823","phase":"PHASE2","title":"Ziv-aflibercept Efficacy in Better Regulating AMD","status":"COMPLETED","sponsor":"Kapil Kapoor","startDate":"2017-07-07","conditions":"Wet Macular Degeneration, Wet Age-related Macular Degeneration","enrollment":62},{"nctId":"NCT02699450","phase":"PHASE2","title":"A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-04-27","conditions":"Diabetic Macular Edema","enrollment":229},{"nctId":"NCT02358889","phase":"PHASE2","title":"Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Iconic Therapeutics, Inc.","startDate":"2015-02","conditions":"Choroidal Neovascularization, Age-related Macular Degeneration","enrollment":88},{"nctId":"NCT01306981","phase":"PHASE4","title":"Ranibizumab in Diabetic Vitrectomy. A Prospective, Randomised Controlled Trial of Ranibizumab Pre-treatment in Diabetic Vitrectomy - a Pilot Study","status":"COMPLETED","sponsor":"Moorfields Eye Hospital NHS Foundation Trust","startDate":"2011-03-30","conditions":"Diabetic Retinopathy, Retinal Neovascularisation","enrollment":30},{"nctId":"NCT01835067","phase":"PHASE2, PHASE3","title":"Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular AMD","status":"COMPLETED","sponsor":"King's College Hospital NHS Trust","startDate":"2014-09","conditions":"Exudative Macular Degeneration, Retinal Hemorrhage","enrollment":55},{"nctId":"NCT04464694","phase":"PHASE4","title":"Pre-vitrectomy Intravitreal Ranibizumab for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Edema","status":"UNKNOWN","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2020-09-01","conditions":"Proliferative Diabetic Retinopathy, Diabetic Macular Edema","enrollment":142},{"nctId":"NCT04332133","phase":"NA","title":"Outcomes of Subthreshold Laser Versus Intravitreal Injection of Ranibizumab in Diabetic Macular Edema","status":"COMPLETED","sponsor":"Minia University","startDate":"2016-12","conditions":"Diabetic Macular Edema","enrollment":80},{"nctId":"NCT02953938","phase":"PHASE4","title":"Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-12-15","conditions":"Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)","enrollment":59},{"nctId":"NCT00727038","phase":"PHASE1, PHASE2","title":"Lucentis for New Onset Neovascular Glaucoma","status":"WITHDRAWN","sponsor":"University of Illinois at Chicago","startDate":"2008-01-04","conditions":"Glaucoma, New Onset Glaucoma, Neovascular Glaucoma","enrollment":""},{"nctId":"NCT02665689","phase":"PHASE4","title":"Influence of Diabetes Control on Treatment of Diabetic Macular Edema With Ranibizumab","status":"TERMINATED","sponsor":"Prof. Dr. Antonia M. Joussen","startDate":"2016-01-18","conditions":"Visual Acuity Reduced Transiently, Macular Edema, Cystoid","enrollment":4},{"nctId":"NCT01775124","phase":"PHASE4","title":"Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-02-22","conditions":"Neovascular Age-related Macular Degeneration","enrollment":332},{"nctId":"NCT04062370","phase":"PHASE4","title":"Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-10-01","conditions":"Retinal Vein Occlusion, Treatment, Photocoagulation Burn to Retina","enrollment":100},{"nctId":"NCT03499223","phase":"PHASE2","title":"A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME)","status":"COMPLETED","sponsor":"Oxurion","startDate":"2018-04-20","conditions":"Diabetes Mellitus, Diabetic Retinopathy, Macular Edema","enrollment":70},{"nctId":"NCT03999125","phase":"PHASE4","title":"Anti-VEGF Therapy Versus Dexamethasone Implant for DME","status":"UNKNOWN","sponsor":"Sudhalkar Eye Hospital","startDate":"2019-06-25","conditions":"Clinically Significant Macular Edema Due to Diabetes Mellitus","enrollment":150},{"nctId":"NCT02262260","phase":"PHASE3","title":"Compare Safety/Efficacy of Labeled vs Wait-Extend Regimen of Lucentis in Turkish Patients With VI Due to DME","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-12-12","conditions":"Diabetic Macular Edema","enrollment":87},{"nctId":"NCT01922102","phase":"PHASE3","title":"Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-09-11","conditions":"Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)","enrollment":457},{"nctId":"NCT02398500","phase":"PHASE1, PHASE2","title":"Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2015-07-22","conditions":"Age-related Macular Degeneration (AMD)","enrollment":25},{"nctId":"NCT01748292","phase":"PHASE3","title":"Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab","status":"COMPLETED","sponsor":"Charles C Wykoff, PhD, MD","startDate":"2012-12","conditions":"Macular Degeneration","enrollment":60},{"nctId":"NCT02979665","phase":"","title":"Changes to the Retina Following Anti-VEGF Treatments for Diabetic Macular Edema","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2014-09","conditions":"Diabetic Macular Edema","enrollment":51},{"nctId":"NCT03312283","phase":"PHASE1","title":"Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis® in Patients With Wet AMD","status":"COMPLETED","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2017-12-20","conditions":"Wet Age-related Macular Degeneration","enrollment":48},{"nctId":"NCT01594281","phase":"PHASE2","title":"Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12-11","conditions":"Proliferative Diabetic Retinopathy (PDR)","enrollment":107},{"nctId":"NCT02259088","phase":"PHASE3","title":"A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-11-05","conditions":"Diabetic Macular Edema, Visual Impairment","enrollment":384},{"nctId":"NCT02366468","phase":"PHASE4","title":"Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-02-23","conditions":"Diabetic Retinopathy","enrollment":135},{"nctId":"NCT01968239","phase":"PHASE2","title":"Proof of Concept Study of Re-treatment in BRVO With Ranibizumab Guided by OCT","status":"COMPLETED","sponsor":"University of Leipzig","startDate":"2013-10","conditions":"Branch Retinal Vein Occlusion","enrollment":27},{"nctId":"NCT03759860","phase":"PHASE4","title":"Laser (Selective Retina Therapy) and Drug Combined Intervention in Clinically Significant Diabetic Macular Edema","status":"UNKNOWN","sponsor":"CynosureLutronic","startDate":"2018-01-08","conditions":"Diabetic Macular Edema","enrollment":12},{"nctId":"NCT02806752","phase":"PHASE4","title":"Intravitreal Ranibizumab and TA Combination Therapy vs. Ranibizumab Monotherapy in Polypoidal Choroidal Vasculopathy","status":"UNKNOWN","sponsor":"Aier School of Ophthalmology, Central South University","startDate":"2017-01","conditions":"Wet Macular Degeneration","enrollment":120},{"nctId":"NCT02375971","phase":"PHASE3","title":"RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-12-30","conditions":"Retinopathy of Prematurity","enrollment":224},{"nctId":"NCT01030770","phase":"PHASE2, PHASE3","title":"Preoperative Intravitreal Ranibizumab for Persistent Diabetic Vitreous Haemorrhage:","status":"COMPLETED","sponsor":"King's College Hospital NHS Trust","startDate":"2010-07","conditions":"Diabetes Complications","enrollment":25},{"nctId":"NCT02355028","phase":"PHASE2","title":"LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Alcon, a Novartis Company","startDate":"2015-03-03","conditions":"Exudative Age-Related Macular Degeneration","enrollment":136},{"nctId":"NCT03495765","phase":"PHASE3","title":"To Evaluate the Comparative Efficacy of Lucentis (Ranibizumab) 0.5mg Intravitreal Injection in Patients With Diabetic Macular Oedema (DME) With Well Controlled and Poorly Controlled Diabetes Mellitus","status":"COMPLETED","sponsor":"Marsden Eye Specialists","startDate":"2011-03","conditions":"Diabetic Macular Oedema","enrollment":160},{"nctId":"NCT01134055","phase":"PHASE2","title":"Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-06-01","conditions":"Macular Degeneration","enrollment":510},{"nctId":"NCT02843490","phase":"PHASE4","title":"Functional and Structural Outcomes in Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Johannes Gutenberg University Mainz","startDate":"2016-08-05","conditions":"Neovascular Age-related Macular Degeneration","enrollment":71},{"nctId":"NCT02577107","phase":"PHASE4","title":"Head to Head Study of Anti-VEGF Treatment.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-01-13","conditions":"Age-related Macular Degeneration","enrollment":12},{"nctId":"NCT02857491","phase":"NA","title":"Intravitreal Injection of Ranibizumab Versus Sham Before Vitrectomy in Patients With Proliferative Diabetic Retinopathy","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2014-07","conditions":"Proliferative Diabetic Retinopathy","enrollment":90},{"nctId":"NCT01494805","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Lions Eye Institute, Perth, Western Australia","startDate":"2011-12","conditions":"Macular Degeneration, Age-related Maculopathies, Age-related Maculopathy","enrollment":40},{"nctId":"NCT03261635","phase":"PHASE4","title":"Ranibizumab Plus Indomethacin","status":"COMPLETED","sponsor":"Università degli Studi di Brescia","startDate":"2016-01-07","conditions":"Macular Edema","enrollment":58},{"nctId":"NCT00485836","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2007-07","conditions":"Macular Edema, Retinal Vein Occlusion","enrollment":392},{"nctId":"NCT01976312","phase":"PHASE3","title":"Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-11-12","conditions":"Central Retinal Vein Occlusion","enrollment":252},{"nctId":"NCT00486018","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2007-07","conditions":"Macular Edema, Retinal Vein Occlusion","enrollment":397},{"nctId":"NCT01976338","phase":"PHASE3","title":"Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-11-12","conditions":"Macular Edema Secondary to Branch Retinal Vein Occlusion","enrollment":283},{"nctId":"NCT00473330","phase":"PHASE3","title":"A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2007-06","conditions":"Diabetes Mellitus, Macular Edema","enrollment":377},{"nctId":"NCT00473382","phase":"PHASE3","title":"A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2007-06","conditions":"Diabetes Mellitus, Macular Edema","enrollment":382},{"nctId":"NCT02050828","phase":"PHASE2","title":"The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Aerpio Therapeutics","startDate":"2014-01","conditions":"Diabetic Macular Edema (DME)","enrollment":144},{"nctId":"NCT00901186","phase":"PHASE2","title":"Efficacy and Safety of Ranibizumab (Intravitreal Injections) Versus Laser Treatment in Patients With Visual Impairment Due to Diabetic Macular Edema","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-11","conditions":"Diabetic Macular Edema, Visual Impairment","enrollment":83},{"nctId":"NCT02067013","phase":"PHASE2","title":"Analysis of Aqueous and Vitreous Humor","status":"UNKNOWN","sponsor":"California Retina Consultants","startDate":"2015-07","conditions":"Proliferative Diabetic Retinopathy, Macular Degeneration, Macular Hole","enrollment":45},{"nctId":"NCT02059772","phase":"PHASE4","title":"Combination of Standard Lucentis Therapy With Micropulse Diode Laser for the Treatment of Diabetic Macular Edema","status":"UNKNOWN","sponsor":"GWT-TUD GmbH","startDate":"2014-04-30","conditions":"Diabetic Macular Edema","enrollment":25},{"nctId":"NCT01599650","phase":"PHASE3","title":"Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-05","conditions":"Branch Retinal Vein Occlusion","enrollment":455},{"nctId":"NCT01414153","phase":"PHASE2","title":"Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD","status":"COMPLETED","sponsor":"Lpath, Inc.","startDate":"2012-08","conditions":"Exudative Age-related Macular Degeneration","enrollment":158},{"nctId":"NCT01994291","phase":"PHASE2","title":"A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema","status":"TERMINATED","sponsor":"Pfizer","startDate":"2013-11","conditions":"Macular Edema, Diabetic","enrollment":199},{"nctId":"NCT02914626","phase":"PHASE3","title":"Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled Study","status":"UNKNOWN","sponsor":"LEANDRO CABRAL ZACHARIAS","startDate":"2016-10","conditions":"Glaucoma, Neovascular, Ranibizumab","enrollment":28},{"nctId":"NCT01840410","phase":"PHASE3","title":"Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-09","conditions":"Choroidal Neovascularization (CNV)","enrollment":183},{"nctId":"NCT02349516","phase":"PHASE2","title":"Squalamine Lactate Eye Drops in Combination With Ranibizumab in Patients With Diabetic Macular Edema (DME)","status":"WITHDRAWN","sponsor":"Starr Muscle","startDate":"2015-02","conditions":"Diabetic Retinopathy","enrollment":""},{"nctId":"NCT01846299","phase":"PHASE3","title":"To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-10","conditions":"Macular Edema (ME)","enrollment":181},{"nctId":"NCT01169909","phase":"PHASE1","title":"Efficacy and Safety of Sub-tenon Ranibizumab for Recurrent Pterygia","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2010-08","conditions":"Pterygium","enrollment":10},{"nctId":"NCT02121353","phase":"PHASE1, PHASE2","title":"Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration","status":"COMPLETED","sponsor":"Pfenex, Inc","startDate":"2013-11","conditions":"Age Related Macular Degeneration (AMD)","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ranibizumab Control","genericName":"Ranibizumab Control","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ranibizumab is a monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and vascular permeability in the eye. Used for Age-related macular degeneration (wet/neovascular), Diabetic macular edema, Retinal vein occlusion.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}